Posted by cv6-admin
CV6 Therapeutics
Professor Iain McInnes CBE is Vice Principal and Head of the College of Medical, Veterinary and Life Sciences, Muirhead Chair of Medicine and Versus Arthritis Professor of Rheumatology at the University of Glasgow. Professor McInnes is an internationally-recognised leader in global research into rheumatoid and psoriatic arthritis having led numerous clinical trials and pathogenesis investigation […]
Posted by pbd-admin
CV6 Therapeutics
Dr Wilson, has over 20 years of experience in cancer research projects focused on identifying mechanisms to improve the effectiveness of chemotherapeutic agents in human cancers. Since 2014, he has held the position of Scientific Director of Drug Development at CV6 Therapeutics (NI) Ltd. Dr Wilson’s research has focused on cellular signaling pathways and the […]
Posted by pbd-admin
CV6 Therapeutics
Dr Lauren Cairns PhD is a research scientist with almost 10 years experience in cancer biology. The primary focus of her research experience was identifying novel repurposed combination therapies for the treatment of paediatric cancers such as AML, ALL and Medulloblastoma. Lauren also successfully implemented a robust multiplex drug screening approach which was later adopted […]
Posted by pbd-admin
CV6 Therapeutics
Dr. Kylie A. McLaughlin PhD has 15 years of experience in the field of biomedical science and oncology. She holds the distinction of being the first scientist to join the CV6 Therapeutics R&D in Northern Ireland in 2015. She currently holds the position of Associate-Principal Scientist within the R&D team. Kylie’s research expertise spans drug […]
Posted by pbd-admin
CV6 Therapeutics
Dr Declan Doherty PhD has over 16 years of experience working in both academic and industrial research laboratories. He has worked at Ulster University, Queens University Belfast, Fusion Antibodies PLC and Almac Diagnostics Ltd. Since November 2022, he has held the position of Senior Scientist at CV6 Therapeutics (NI) Ltd where he is currently investigating […]
Posted by pbd-admin
CV6 Therapeutics
Sebastian Stintzing, MD, currently serves as a distinguished Professor of Medicine and leads the Department of Hematology, Oncology, and Tumor Immunology within the CCM at Charité Universitaetsmedizin Berlin. His professional focus involves identifying predictive and prognostic biomarkers in gastrointestinal cancer treatment. In 2012, he was awarded the esteemed Research Fellowship Award from “Deutsche Krebshilfe” (German […]
Posted by cv6-admin
CV6 Therapeutics
Chris E. Rivera is currently the President, CEO and Chairman of the Board of Nativis Inc. He has over 30 years’ experience in the development and manufacturing of pharmaceutical and medical devices. Whilst at the Washington Biotechnology and Biomedical Association he established the commercialization programs of more than 400 emerging biotechnology companies. Chris was the […]
Posted by cv6-admin
CV6 Therapeutics
Richard ‘Dick’ Milliken is the Chairman of Catalyst Inc., (formerly the Northern Ireland Science Park), and the Lotus Group Ltd. He is a Non-Executive Director of Ryanair Plc and the Bank of Ireland Mortgage Bank. In addition, Dick mentors a number of smaller early stage growth companies based in Northern Ireland. Previously, Dick was the […]
Posted by cv6-admin
CV6 Therapeutics
Paul Workman, PhD is Chief Executive and President of The Institute of Cancer Research (ICR), London. He is Harrap Professor of Pharmacology and Therapeutics at the ICR, as well as the former Head of the Division of Cancer Therapeutics and former Director of the Cancer Research UK Cancer Therapeutics Unit from 1997-2016. Paul is also […]
Posted by cv6-admin
CV6 Therapeutics
Ruth Plummer is Professor of Experimental Cancer Medicine at the Newcastle University and Director of the Sir Bobby Robson Cancer Trials Research Centre. She leads the Newcastle Experimental Cancer Medicine Centre and also the CRUK Newcastle Cancer Centre. Her research interests are in the field of DNA repair and early phase clinical trials of novel […]
